Related Experiment Video
Updated: May 28, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Metabolomic screening and identification of the bioactivation pathways of ritonavir
1Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
Abstract:
Ritonavir-boosted protease inhibitor regimens are widely used for HIV chemotherapy. However, ritonavir causes multiple side effects, and the mechanisms are not fully understood. The current study was designed to explore the metabolic pathways of ritonavir that may be related to its toxicity. Metabolomic analysis screened out 26 ritonavir metabolites in mice, and half of them are novel. These novel ritonavir metabolites include two glycine conjugated, two N-acetylcysteine conjugated, and three ring-open products. Accompanied with the generation of ritonavir ring-open metabolites, the formation of methanethioamide and 2-methylpropanethioamide were expected. Upon the basis of the structures of these novel metabolites, five bioactivation pathways are proposed, which may be associated with sulfation and epoxidation. By using Cyp3a-null mice, we confirmed that CYP3A is involved in four pathways of RTV bioactivation. In addition, all these five bioactivation pathways were recapitulated in the incubation of ritonavir in human liver microsomes. Further studies are suggested to determine the role of CYP3A and these bioactivation pathways in ritonavir toxicity.
Insights
Ritonavir (RTV) causes side effects through unknown metabolic pathways. This study identified novel RTV metabolites and proposed five bioactivation pathways, with CYP3A involvement confirmed in mice and human liver microsomes.
Area of Science:
- Pharmacology
- Metabolomics
- Toxicology
Background:
- Ritonavir-boosted protease inhibitors are crucial for HIV treatment.
- The mechanisms underlying ritonavir's toxicity remain unclear.
- Understanding ritonavir metabolism is key to mitigating its side effects.
Purpose of the Study:
- To investigate the metabolic pathways of ritonavir.
- To identify novel ritonavir metabolites.
- To explore potential bioactivation pathways linked to ritonavir toxicity.
Main Methods:
- Metabolomic analysis in mice to identify ritonavir metabolites.
- Structural elucidation of novel metabolites.
- Involvement of Cytochrome P450 3A (CYP3A) assessed using Cyp3a-null mice.
- Recapitulation of pathways in human liver microsomes.
Main Results:
- Identified 26 ritonavir metabolites in mice, with 13 being novel.
- Novel metabolites include glycine and N-acetylcysteine conjugates, and ring-open products.
- Proposed five potential bioactivation pathways involving sulfation and epoxidation.
- Confirmed CYP3A involvement in four bioactivation pathways.
- All five pathways were observed in human liver microsomes.
Conclusions:
- Novel ritonavir metabolites and bioactivation pathways have been identified.
- CYP3A plays a significant role in ritonavir bioactivation.
- These findings provide insights into ritonavir-induced toxicity.
- Further research is warranted to elucidate the precise role of CYP3A and these pathways in ritonavir toxicity.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Rapid Identification of Pathogens

